Location: Home
  • search
  • go
  • Relate News
  • 7/8/2021Revision of China's Anti-Monopoly Law to Close "Loopholes" in Anti-car...
  • 7/8/2021Is China's Drug Regulator Suddenly Raising the Bar on Cancer Med R&D? ...
  • 7/7/2021dMed-Clinipace Completes US$50M Series C+ Financing
  • 7/6/2021NMPA Announces Package Insert Revision of Metoclopramide Products
  • 7/6/2021Innovent and Laekna Enter a Partnership to Co-Develop Combo of Sinti...
  • 7/6/2021CStone Granted Chinese IND Approval for I/O Candidate CS2006/NM21-14...
  • 7/6/2021Y-mAbs Submits Chinese BLA for DANYELZA® (naxitamab-gqgk)
  • 7/5/2021GSK Launches HIV Drug Dovato (dolutegravir/lamivudine) in China
  • 7/5/2021Nicox Amends Deal with Ocumension with $2M Upfront
  • 7/2/2021NDRC Issues the Implementation Plan for Infrastructural Building of th...
  • 7/2/2021At A Glance: Pharmaceutical Merger Review in China
  • 6/30/2021HUTCHMED Launches $325M Initial Public Offering in Hong Kong
  • 6/30/2021Recent Executive Moves
  • 6/30/2021IQVIA: Potential of Chinese Pharma Lies in the Country's Huge Patient ...
  • 6/30/2021IQVIA: Chinese Retail Pharmacy Sales Down 1.4% in Q1/2021
  • 6/30/2021Listed Domestic Pharma Cos See Sharp Performance Growth in Q1
  • 6/30/2021Financial-related Company News in Brief
  • 6/29/2021Innovent Granted Chinese Approval of TYVYT in Combo with BYVASDA as...
  • 6/29/2021Vivoryon and Simcere Announce Licensing Deal for N3pE Amyloid-targetin...
  • 6/28/2021WuXi STA Plans Pharmaceutical Chemical Facility in Delaware
  • 6/28/2021PharmaDJ's China Biotech Fundraising Tracker: April 2021
  • 6/25/2021AZ's Pulmicort, Bayer's Xarelto Among Big Losers in China's Largest Ro...
  • 6/24/2021NMPA Issues the Provisions for Registration of Licensed Pharmacists
  • 6/24/2021China Concludes the 5th Round of National Level VBP, Slashing Average ...
  • 6/24/2021NMPA Revises Packages Insert of Oxiracetam Formulations and Injectable...
  • 6/23/2021Online Platform Operator Medlive Tech Advances Plans for Hong Kong IPO
  • 6/23/2021HUTCHMED's Orpathys Conditionally Approved in China for NSCLC
  • 6/23/2021Innovent's Sintilimab in Combo with Chemotherapy Meets Primary Endpoin...
  • 6/22/2021Innovent's Pemazyre (pemigatinib) Approved in Taiwan
  • 6/22/2021Hutchmed Granted Chinese Approval of Surufatinib (Sulanda) for Advance...
  • Page:87/357 Total number of articles:10681: [First][<<] [85] [86] [87] [88] [89] [>>] [End]
  • Site map | Contact Us | Links
  • © Wicon International Group